Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label, Single-dose, 3-period Crossover, Pharmacokinetic Study Designed to Compare the Systemic Des-ciclesonide Exposure of OMNARIS™ (Ciclesonide) Nasal Spray, Ciclesonide HFA Nasal Aerosol, and Orally Inhaled Ciclesonide
Conditions
Interventions
Ciclesonide
Locations
1
United States
ALTANA Pharma
Austin, Texas, United States
Start Date
April 1, 2007
Primary Completion Date
April 1, 2008
Completion Date
April 1, 2008
Last Updated
February 9, 2023
NCT07419230
NCT06732414
NCT05494346
NCT07110311
NCT04815668
NCT06846385
Lead Sponsor
Covis Pharma S.à.r.l.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions